Icariin and related metabolites in fibrosis management: pharmacological properties and molecular mechanism
Fibrosis is a pathological hallmark of various chronic diseases and contributes significantly to organ dysfunction and poor clinical outcomes. Despite the availability of antifibrotic agents, their limited efficacy and adverse side effect profiles underscore the urgent need for safer and more effect...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1619581/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849736163867230208 |
|---|---|
| author | Jiarui Zhao Wei Zhang |
| author_facet | Jiarui Zhao Wei Zhang |
| author_sort | Jiarui Zhao |
| collection | DOAJ |
| description | Fibrosis is a pathological hallmark of various chronic diseases and contributes significantly to organ dysfunction and poor clinical outcomes. Despite the availability of antifibrotic agents, their limited efficacy and adverse side effect profiles underscore the urgent need for safer and more effective therapeutic alternatives. Traditional Chinese medicines have emerged as promising candidates for fibrosis management. Epimedium, widely used in traditional Chinese medicine, exhibits notable antifibrotic activity, primarily attributed to its bioactive flavonoid icariin (ICA). However, the clinical application of ICA is hindered by its low bioavailability. Recent advances in extraction methods and drug delivery systems have improved the pharmacokinetic properties of ICA and related active metabolites, including icaritin and icariside II. These metabolites exert antifibrotic effects through multifaceted mechanisms, including anti-inflammatory and antioxidant activities, mitochondrial function modulation, apoptosis regulation, and autophagy. This review summarizes current insights into the molecular pathways through which ICA and related metabolites attenuate fibrosis, thereby supporting their potential for clinical translation in antifibrotic therapy. |
| format | Article |
| id | doaj-art-3dc41afc84634b5a9fe1d1fbe4ba5f8a |
| institution | DOAJ |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-3dc41afc84634b5a9fe1d1fbe4ba5f8a2025-08-20T03:07:21ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-06-011610.3389/fphar.2025.16195811619581Icariin and related metabolites in fibrosis management: pharmacological properties and molecular mechanismJiarui ZhaoWei ZhangFibrosis is a pathological hallmark of various chronic diseases and contributes significantly to organ dysfunction and poor clinical outcomes. Despite the availability of antifibrotic agents, their limited efficacy and adverse side effect profiles underscore the urgent need for safer and more effective therapeutic alternatives. Traditional Chinese medicines have emerged as promising candidates for fibrosis management. Epimedium, widely used in traditional Chinese medicine, exhibits notable antifibrotic activity, primarily attributed to its bioactive flavonoid icariin (ICA). However, the clinical application of ICA is hindered by its low bioavailability. Recent advances in extraction methods and drug delivery systems have improved the pharmacokinetic properties of ICA and related active metabolites, including icaritin and icariside II. These metabolites exert antifibrotic effects through multifaceted mechanisms, including anti-inflammatory and antioxidant activities, mitochondrial function modulation, apoptosis regulation, and autophagy. This review summarizes current insights into the molecular pathways through which ICA and related metabolites attenuate fibrosis, thereby supporting their potential for clinical translation in antifibrotic therapy.https://www.frontiersin.org/articles/10.3389/fphar.2025.1619581/fullicariinicariside IIicaritinfibrosispharmacokineticsmolecular mechanism |
| spellingShingle | Jiarui Zhao Wei Zhang Icariin and related metabolites in fibrosis management: pharmacological properties and molecular mechanism Frontiers in Pharmacology icariin icariside II icaritin fibrosis pharmacokinetics molecular mechanism |
| title | Icariin and related metabolites in fibrosis management: pharmacological properties and molecular mechanism |
| title_full | Icariin and related metabolites in fibrosis management: pharmacological properties and molecular mechanism |
| title_fullStr | Icariin and related metabolites in fibrosis management: pharmacological properties and molecular mechanism |
| title_full_unstemmed | Icariin and related metabolites in fibrosis management: pharmacological properties and molecular mechanism |
| title_short | Icariin and related metabolites in fibrosis management: pharmacological properties and molecular mechanism |
| title_sort | icariin and related metabolites in fibrosis management pharmacological properties and molecular mechanism |
| topic | icariin icariside II icaritin fibrosis pharmacokinetics molecular mechanism |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1619581/full |
| work_keys_str_mv | AT jiaruizhao icariinandrelatedmetabolitesinfibrosismanagementpharmacologicalpropertiesandmolecularmechanism AT weizhang icariinandrelatedmetabolitesinfibrosismanagementpharmacologicalpropertiesandmolecularmechanism |